REVIV3 Procare Company Reports Record Fiscal Year 2023 Financial Results
Reviv3 Procare Company reported a significant increase in net sales for the fiscal year ended May 31, 2023, with a growth of 907% to $23.52 million compared to the previous year. Gross profit also improved to 75.3% of sales, up from 64.5% in the prior year. Operating expenses decreased to 66.9% of net revenues, down from 73.6% in the prior year.
Positive
Net sales increased by 907% to $23.52 million for the fiscal year, indicating strong revenue growth.
Gross profit improved to 75.3% of sales, indicating higher profitability.
Operating expenses decreased to 66.9% of net revenues, suggesting improved cost management.
08/22/2023 - 08:00 AM
Net sales (revenue) up 907% to $23.52 million for the fiscal year ended May 31, 2023, as compared to the prior year period without the AXIL® business segment Gross profit (as a percentage of sales) increased to 75.3% for the year, as compared to 64.5% for the prior year period Operating expenses as a percentage of net revenues decreased to 66.9% as compared to 73.6% for the prior year period LOS ANGELES, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Reviv3 Procare Company (“Reviv3,” “we,” “us,” “our,” or the “Company”) (OTCQB: RVIV), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the fiscal year ended May 31, 2023 (“fiscal 2023”).
“As previously disclosed in June 2022, we completed the acquisition of substantially all of the assets of Axil & Associated Brands Corp., a leader in hearing and audio enhancement and protection,” commented Jeff Toghraie, CEO. “The AXIL acquisition fundamentally changed our business model and has led to meaningful growth and laid the foundation for future long-term sustainable growth for the combined Company. As we look to the fiscal year ending 2024 and beyond, we hope to continue to build upon our business model emphasizing innovative products and operational efficiencies to pragmatically grow the business. We have a wonderful shareholder base, world class customers and committed employees – we are excited for what is to come,” stated Mr. Toghraie.
“We had a strong finish to our fiscal year and achieved the milestone of four consecutive quarters of profitability with record year-end revenues and net income,” remarked Monica Diaz Brickell, CFO. “AXIL has been beyond additive to our business and after the successful integration of AXIL and its staff, our revenue grew by an impressive 907% from the prior year. These results underscore the strength of the acquisition - a credit to the AXIL staff, our legacy staff and our management team. During fiscal 2023, we managed to increase our gross profit as a percentage of sales to over 75% from around 64% for the prior year, while reducing our operating expense to less than 67% compared to prior year’s 73% - a meaningful financial achievement. As we look to 2024, we have a goal of accelerating revenue growth and market share expansion,” concluded Ms. Brickell.
Business and Product Success Stories for fiscal 2023
Our primary business model focused on AXIL® during fiscal 2023. We continue to operate the Reviv3 brand in addition to AXIL®, but our focus in the fiscal year ending May 31, 2024 will be on AXIL®.
On June 22, 2022, we announced the acquisition of AXIL®, as noted above. On January 25, 2023, we announced our expanded relationship with “Bass Pro Shops®” with the introduction of “AXIL GS Extreme 2.0 Nationwide®.” On January 31, 2023, we announced a new distribution agreement with JAMMAS SP. O.O. for distribution of AXIL® portfolio of products in Poland. On February 16, 2023, we announced expanded distribution of AXIL® products through distribution agreement with “GMK Ltd.,” for United Kingdom. On February 22, 2023, we announced accelerated European rollout of our AXIL® product line through a new distribution agreement in Switzerland with “Tagforce AG”, which provided us with a streamlined supply chain in Europe. On February 28, 2023, we announced an exclusive agreement with “Berretta Holding” for distribution of AXIL® products in Australia. On April 17, 2023, we announced a new distribution agreement for AXIL® products with “DEFSEC SYSTEMS” for Malaysia. On May 1, 2023, we announced a new distribution agreement of AXIL® products with “FARM SRL” for Italy. On May 10, 2023, we announced the release of the next generation “XCOR True Wireless EarPro Buds®” hearing enhancement and protection by AXIL®. On May 15, 2023, we announced a multi-year licensing agreement with NASCAR®. Financial Tables
REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS May 31, May 31, ASSETS CURRENT ASSETS: Cash $ 4,832,682 $ 373,731 Accounts receivable, net 417,016 105,921 Inventory, net 1,311,864 323,388 Prepaid expenses and other current assets 801,360 — Total Current Assets 7,362,922 803,040 OTHER ASSETS: Property and equipment, net 157,463 29,145 Intangible assets, net 382,674 — Right of use asset 101,845 45,453 Other assets 12,195 16,277 Goodwill 2,152,215 — Total Other Assets 2,806,392 90,875 TOTAL ASSETS $ 10,169,314 $ 893,915 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 908,606 $ 458,263 Customer deposits 183,688 16,522 Equipment payable, current 2,200 3,300 Contract liabilities, current 827,106 — Notes payable 172,588 156,300 Due to related party 158,072 25,452 Lease Liability, current 65,824 47,166 Income Tax Liability 230,913 — Other current liabilities 305,664 — Total Current Liabilities 2,854,661 707,003 LONG TERM LIABILITIES: Equipment payable — 2,200 Lease liability, long term 36,752 — Contract liabilities, long term 605,942 — Total Long Term Liabilities 642,694 2,200 Total Liabilities 3,497,355 709,203 STOCKHOLDERS’ EQUITY: Preferred stock, $0.00 01 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively 25,000 — Common stock, $0.00 01 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively 11,708 4,195 Additional paid-in capital 10,102,243 5,472,084 Accumulated deficit (3,466,992 ) (5,291,567 ) Total Stockholders’ Equity 6,671,959 184,712 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 10,169,314 $ 893,915
REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS For the Fiscal Years Ended May 31, May 31, 2023 2022 Sales, net $ 23,521,027 $ 2,336,257 Cost of sales 5,810,216 828,586 Gross profit 17,710,811 1,507,671 OPERATING EXPENSES: Marketing and selling expenses 11,675,206 1,199,305 Compensation and related taxes 1,347,839 15,129 Professional and consulting expenses 1,420,990 232,774 General and administrative 1,282,565 271,866 Total Operating Expenses 15,726,600 1,719,074 INCOME (LOSS) FROM OPERATIONS 1,984,211 (211,403 ) OTHER INCOME (EXPENSE): Gain on debt settlement 50,500 35,000 Other income 16,829 — Interest income 6,469 36 Interest expense and other finance charges (2,521 ) (6,536 ) Other Income (Expense), Net 71,277 28,500 INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES 2,055,488 (182,903 ) Provision for income taxes 230,913 — NET INCOME (LOSS) $ 1,824,575 $ (182,903 ) NET INCOME (LOSS) PER COMMON SHARE: Basic $ 0.02 $ (0.00 ) Diluted $ 0.01 $ (0.00 ) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic 112,895,411 41,945,881 Diluted 357,385,274 41,945,881
REVIV3 PROCARE COMPANY AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS For the Fiscal Years Ended May 31, May 31, CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) $ 1,824,575 $ (182,903 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 95,179 7,871 Bad debts 76,969 6,941 Inventory obsolescence — 71,481 Stock based compensation 207,342 21,967 Gain on debt forgiveness (50,500 ) (35,000 ) Non cash lease expense — (1,713 ) Change in operating assets and liabilities: Accounts receivable (160,277 ) (21,985 ) Inventory 353,985 95,983 Prepaid expenses and other current assets (661,115 ) 2,430 Deposits (3,810 ) — Accounts payable and accrued expenses 215,175 (701 ) Other current liabilities 630,897 — Customer deposits — (90,426 ) Contract liabilities 389,716 — NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 2,918,136 (126,055 ) CASH FLOWS FROM INVESTING ACTIVITIES Cash acquired on business acquisition 1,066,414 — Purchase of property and equipment (65,650 ) — NET CASH PROVIDED BY INVESTING ACTIVITIES 1,000,764 — CASH FLOWS FROM FINANCING ACTIVITIES Cash raised for common stock to be issued 447,850 — Proceeds from loan payable — 35,000 Repayment of equipment financing (3,300 ) (3,300 ) Repayment of note payable (37,119 ) — Advances (payments) from a related party 132,620 (28,851 ) NET CASH PROVIDED BY FINANCING ACTIVITIES 540,051 2,849 NET INCREASE (DECREASE) IN CASH 4,458,951 (123,206 ) CASH - Beginning of year 373,731 496,937 CASH - End of year $ 4,832,682 $ 373,731 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid during the period for: Interest $ 2,521 $ 500 Income taxes $ — $ — SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Stock issued for business combination $ 4,007,480 $ — Right of use assets recognized as lease liability $ 131,970 $ — Tangible assets (excluding cash) acquired in business combination $ 1,740,729 $ — Intangible assets acquired in business combination $ 456,945 $ — Goodwill acquired in business combination $ 2,152,215 $ — Liabilities assumed in business combination $ 1,408,823 $ —
About Reviv3
Reviv3 Procare Company (OTCQB: RVIV) is an emerging global e-commerce consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL® brand and premium hair and skincare products under its in-house Reviv3 Procare brand - selling products in the United States, Canada, the European Union and throughout Asia. To learn more, please visit the Company's website at www.reviv3.com www.goaxil.com
Forward-Looking Statements
This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as “future,” “hope” and “goal,” among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management’s beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management’s control and may cause Reviv3’s results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3’s ability to grow net sales as anticipated and perform in accordance with guidance; (ii) our ability to generate sufficient revenue to support Reviv3’s operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives, including integrating the AXIL® brand; (iv) Reviv3’s ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of Reviv3’s customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3’s product costs and other costs of doing business, and reduce Reviv3’s earnings; and (vi) the impact of unstable market and general economic conditions on Reviv3’s business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and ongoing impact of COVID-19, and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Investor Relations:
